[go: up one dir, main page]

WO2024023198A1 - Réduction de l'effet de l'entérite nécrotique chez un oiseau à l'aide d'une préparation d'oligosaccharide - Google Patents

Réduction de l'effet de l'entérite nécrotique chez un oiseau à l'aide d'une préparation d'oligosaccharide Download PDF

Info

Publication number
WO2024023198A1
WO2024023198A1 PCT/EP2023/070807 EP2023070807W WO2024023198A1 WO 2024023198 A1 WO2024023198 A1 WO 2024023198A1 EP 2023070807 W EP2023070807 W EP 2023070807W WO 2024023198 A1 WO2024023198 A1 WO 2024023198A1
Authority
WO
WIPO (PCT)
Prior art keywords
mol
oligosaccharide preparation
bird
anhydro
necrotic enteritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/070807
Other languages
English (en)
Inventor
Elkin AMAYA
Britt BLOKKER
Cristiano BORTOLUZZI
John Michael Geremia
Jose-Otavio SORBARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to EP23751275.1A priority Critical patent/EP4561588A1/fr
Priority to CN202380055941.2A priority patent/CN119604295A/zh
Publication of WO2024023198A1 publication Critical patent/WO2024023198A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present invention relates to a method for reducing necrotic enteritis effect in a bird and to a use of the oligosaccharide preparation.
  • necrotic enteritis is one of the most common diseases in poultry farming, causing severe consequences for affected animals as well as financial losses for the agriculturist. Necrotic enteritis usually occurs in broiler chickens, but has also been described in other birds such as layer chickens or turkeys. In the event of a clinical outbreak, necrotic enteritis causes mortality rates of up to 50%. In addition, necrotic enteritis typically causes inter alia intestinal lesions, and negatively affects animal welfare as well as animal performance, such as reduced body weight gain or increased feed conversion ratio. Financial losses due to necrotic enteritis are estimated at five to six billion USD per year.
  • Necrotic enteritis is caused by atypically high intestinal growth of Clostridium perfringens. Under normal conditions, C. perfringens is a regular member of a bird's intestinal microbiome. However, under certain conditions, over proliferation of C. perfringens can be induced, accompanied with toxin production by C. perfringens. Conditions known to favor such over proliferation include consumption of feed contaminated with mycotoxin, coccidiosis stress from Eimeria contamination and/or vaccination, immune repression, low-quality protein, reduced amino acid digestibility or nutrient absorption, increased protein availability in the lumen, reduced gut integrity, protein leakage, or pathogen translocation.
  • a method for reducing necrotic enteritis effect in a bird comprising the step of administering an oligosaccharide preparation to a bird in need of reducing necrotic enteritis effect, wherein the oligosaccharide preparation comprises at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n, wherein n is an integer greater than or equal to 2; and wherein each fraction comprises from at least about 0.5% to about 90% (e.g. from 1% to 90%; or e.g. from about 0.5% to about 15%) of anhydrosubunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • the at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n can be referred to as DP1 to DPn fractions.
  • the invention relates to a use of an oligosaccharide preparation for reducing necrotic enteritis effect in a bird in need thereof, wherein the oligosaccharide preparation comprises at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than or equal to 2; and wherein each fraction comprises from at least about 0.5% to about 90% (e.g. from 1% to 90%; or e.g. from about 0.5% to about 15%) of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • said oligosaccharide preparation is used for administration to a bird in need of reducing necrotic enteritis effect.
  • the invention relates to an oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof, wherein the oligosaccharide preparation comprises at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than or equal to 2; and wherein each fraction comprises from at least about 0.5% to about 90% (e.g. from 1 % to 90%; or e.g. from about 0.5% to about 15%) of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • DP1 to DPn fractions a distinct degree of polymerization selected from 1 to n
  • n is an integer greater than or equal to 2
  • each fraction comprises from at least about 0.5% to about 90% (e.g. from 1 % to 90%; or e.g. from
  • the necrotic enteritis effect is at least one selected from the group of reduced body weight gain of the bird in need of reducing necrotic enteritis effect compared to a control bird not in need of reducing necrotic enteritis effect; increased feed conversion ratio of the bird in need of reducing necrotic enteritis effect compared to the control bird; increased mortality (in particular increased necrotic enteritis-related mortality) of the bird in need of reducing necrotic enteritis effect compared to the control bird; and increased lesion score of the bird in need of reducing necrotic enteritis effect compared to the control bird.
  • the bird in need of reducing necrotic enteritis effect is challenged by Clostridium perfringens.
  • Such challenge by Clostridium perfringens consists in an atypically high occurrence of intestinal Clostridium perfringens.
  • the C. perfringens challenge due to C.
  • perfringens over proliferation is a result of one or more of the following: consumption of feed contaminated with mycotoxin(s), coccidiosis stress from Eimeria contamination and/or vaccination against coccidiosis, immune repression, intake of low-quality protein, reduced amino acid digestibility or nutrient absorption, increased protein availability in the lumen, reduced gut integrity, protein leakage, or pathogen translocation; thus causing a need for reducing necrotic enteritis effect.
  • the bird is poultry, e.g. chicken, duck, goose, turkey, guinea fowl, pigeon, quail.
  • the bird is chicken, preferably broiler chicken.
  • the necrotic enteritis effect is reduced on at least one day within 42 days after a first administration of the oligosaccharide preparation, selected from the group of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42 day(s).
  • the necrotic enteritis effect is reduced when compared to the day on which the bird in need of reducing necrotic enteritis effect is first administered the oligosaccharide preparation (i.e. day 1).
  • day 14 indicates the fourteenth day after the bird in need of reducing necrotic enteritis effect is first administered the oligosaccharide preparation (i.e. after day 1);
  • day 21 indicates the twenty-first day after the bird in need of reducing necrotic enteritis effect is first administered the oligosaccharide preparation (i.e. after day 1); etc.
  • the oligosaccharide preparation is comprised in a nutritional composition administered to the bird.
  • the oligosaccharide preparation is comprised in the nutritional composition at an inclusion rate of at least 50 ppm, e.g. at least 50, 70, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900 ppm.
  • the oligosaccharide preparation is comprised in the nutritional composition at a concentration of at least 50 ppm (e.g at least 100, 150, 200, 220, 250, 300, 310, 350, 400 ppm) of dried glycans of the oligosaccharide preparation.
  • the oligosaccharide preparation is administered to the bird before, after, and/or simultaneously with the diet of the bird in need of reducing necrotic enteritis effect , preferably simultaneously with the diet.
  • the step of administering an oligosaccharide preparation to a bird in need of reducing necrotic enteritis effect as described herein is intended to be construed as providing the oligosaccharide preparation (e.g. as a part comprised in a nutritional composition) to the bird for consumption by said bird.
  • the oligosaccharide preparation is fed to the bird.
  • this administering/providing/feeding may be effected by providing the nutritional composition to the bird in an ad libitum feeding fashion.
  • administering the oligosaccharide preparation comprises providing the oligosaccharide preparation to a bird such that the bird may ingest the oligosaccharide preparation at will.
  • the animal ingests at least some portion of the oligosaccharide preparation.
  • the oligosaccharide preparation may be provided to the bird on any appropriate schedule.
  • the bird is provided the oligosaccharide preparation on a daily basis, on a weekly basis, on a monthly basis, on an every other day basis, for at least three days out of every week, or for at least seven days out of every month.
  • the oligosaccharide preparation is administered to the bird multiple times in a day.
  • the oligosaccharide preparation is administered to the bird at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a day.
  • the oligosaccharide preparation is administered to the bird at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a day.
  • the oligosaccharide preparation is administered to the bird at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 times a week.
  • the oligosaccharide preparation is administered to the bird at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 times a week. In some embodiments, the oligosaccharide preparation is administered to the bird every day, every other day, every 3 days, every 4 days, every week, every other week, or every month.
  • the oligosaccharide preparation is administered to the bird at certain time during the day.
  • the oligosaccharide preparation is administered to the bird in the morning, in the afternoon, and/or in the evening, or any combination thereof.
  • the bird is provided the nutritional composition during certain diet phases.
  • some birds are provided a starter diet, e.g. between 0 to 14 days of age.
  • a bird is provided a grower diet, e.g. between 15 to 28 days of age, between 15 to 35 days of age, or between 15 to 39 days of age.
  • a bird is provided a finisher diet, e.g. between 29 to 35 days of age, between 36 to 42 days of age, or between 40 to 46 days of age.
  • the oligosaccharide preparation may be fed to individual birds or a bird population.
  • the oligosaccharide preparation may be fed to an individual poultry or a poultry population.
  • the oligosaccharide preparation may be provided to a bird in any appropriate form, including, for example, in solid form, in liquid form, or a combination thereof. Also in case the oligosaccharide preparation is provided as part of a nutritional composition, said nutritional composition may be provided in any appropriate form, including, for example, in solid form, in liquid form, or a combination thereof.
  • the nutritional composition or the oligosaccharide preparation is a liquid, such as a syrup or a solution.
  • the nutritional composition or the oligosaccharide preparation is a solid, such as pellets or powder.
  • the nutritional composition or the oligosaccharide preparation may be fed to the bird in both liquid and solid components, such as in a mash.
  • the oligosaccharide preparation referred to herein is a synthetic oligosaccharide preparation.
  • the oligosaccharide preparation may be provided in the form of a powderous formulation comprising at least 20% (w/w) (e.g. at least 20, 25, 30, 35, 40, 45 etc. % w/w) of the oligosaccharide preparation as referred to herein; at least 25% (w/w) of a silica-based adsorbate (e.g. diatomaceous earth, amorphous precipitated silica) having an average particle size D of less than or equal to 3000 pm (e.g.
  • a silica-based adsorbate e.g. diatomaceous earth, amorphous precipitated silica
  • such a powderous formulation may comprise 30-70% (w/w) of the oligosaccharide preparation as referred to herein; 30-70% (w/w) of a silica based adsorbate (e.g. having an average particle size of at least 50 pm); and 0-21% (w/w) of water; wherein the % are based on the total weight of the powderous formulation.
  • the oligosaccharide preparation is formulated as described in any one of Examples 22-26 and 33 of WO 2020/097458.
  • n of the oligosaccharide preparation is at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35,
  • At least one fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance; and/or wherein each fraction of the oligosaccharide preparation comprises greater than 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • the oligosaccharide preparation has a weight average molecular weight from about 300 to 5000 g/mol, e.g. from about 2000 to 2800 g/mol, 2100 to 2700 g/mol, 2200 to 2600 g/mol, 2300 to 2500 g/mol, or 2320 to 2420 g/mol; 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1300 g/mol, 400 to 1200 g/mol, 400 to 1100 g/mol, 500 to 1300 g/mol, 500 to 1200 g/mol, 500 to 1100 g/mol, 600 to 1300 g/mol, 600 to 1200 g/mol, or 600 to 1100 g/mol; and/or wherein the oligosaccharide preparation has a number average molecular weight from about 300 to
  • the relative abundance of oligosaccharides in each of the n fractions of the oligosaccharide preparation decreases monotonically with its degree of polymerization
  • oligosaccharide preparations according to the invention are described in WO 2020/097458 and WO 2016/007778, in particular in the Examples described therein, in particular in any one of Examples 1-7, 16-18 of WO 2020/097458 A1 , in the methods described in paragraph [317], and/or in any one of Examples 73-77, 80-89, 97-99, 101- 110 of WO 2016/007778 A1.
  • Oligosaccharide preparations according to the invention are characterized by the step of heating an aqueous composition comprising one or more feed sugars and a catalyst to a temperature and for a time sufficient to induce polymerization.
  • Such oligosaccharide preparations may be termed synthetic oligosaccharide preparations.
  • oligosaccharide preparations as referred to herein are further specified.
  • oligosaccharide preparation may refer to a preparation that comprises one or more oligosaccharides.
  • an “oligosaccharide” or “oligomer” may refer to a monosaccharide or a compound containing two or more monosaccharide subunits linked by glycosidic bonds.
  • An “oligosaccharide” may also refer to an anhydro-monosaccharide or a compound containing two or more monosaccharide subunits, where at least one monosaccharide unit is replaced by an anhydro-subunit.
  • An “oligosaccharide” may be optionally functionalized.
  • oligosaccharide encompasses all species of the oligosaccharide, wherein each of the monosaccharide subunit in the oligosaccharide is independently and optionally functionalized and/or replaced with its corresponding anhydro-monosaccharide subunit.
  • an “anhydro-subunit” may be a product of reversible thermal dehydration of a monosaccharide (or monosaccharide subunit) or a sugar caramelization product.
  • an “anhydro-subunit” may be an anhydro-monosaccharide such as anhydro-glucose.
  • an “anhydro-subunit” may be linked with one or more regular or anhydromonosaccharide subunits via glycosidic linkage.
  • An oligosaccharide may be characterized to contain two or more monosaccharide subunits linked by glycosidic bonds.
  • a “gluco-oligosaccharide” may refer to a glucose or a compound containing two or more glucose monosaccharide subunits linked by glycosidic bonds.
  • a “gluco-oligosaccharide” may also refer to an anhydro-glucose or a compound containing two or more glucose monosaccharide subunits linked by glycosidic bonds, wherein at least one monosaccharide subunit is replaced with an anhydro-glucose subunit.
  • a “galacto-oligosaccharide” may refer to a galactose or a compound containing two or more galactose monosaccharide subunits linked by glycosidic bonds.
  • a “galacto-oligosaccharide” may also refer to an anhydro-galactose or a compound containing two or more galactose monosaccharide subunits linked by glycosidic bonds, wherein at least one monosaccharide subunit is replaced with an anhydro-galactose subunit.
  • a gluco-galactose- oligosaccharide may be a gluco-oligosaccharide, a galacto-oligosaccharide, or a compound containing one or more glucose monosaccharide subunits and one or more galactose monosaccharide subunits linked by glycosidic bonds, wherein at least one of the monosaccharide subunits is replaced with its respective anhydro-monosaccharide subunit.
  • a gluco-galacto-xylo- oligosaccharide may refer to a compound produced by the condensation reaction of glucose, galactose, and xylose.
  • An oligosaccharide preparation comprising gluco-galacto-xylo- oligosaccharides may comprise gluco-galactose-oligosaccharides, gluco-xylo-oligosaccharides, galacto-xylo-oligosaccharides, and compounds containing one or more glucose monosaccharide subunits, one or more xylose monosaccharide subunits, and one or more galactose monosaccharide subunits linked by glycosidic bonds.
  • the term “monosaccharide unit” and “monosaccharide subunit” may be used interchangeably, unless suggested otherwise.
  • a “monosaccharide subunit” may refer to a monosaccharide monomer in an oligosaccharide.
  • the oligosaccharide may be referred to as a monosaccharide subunit or monosaccharide.
  • its monosaccharide subunits are linked via glycosidic bonds.
  • the term “regular monosaccharide” may refer to a monosaccharide that does not contain an anhydro-subunit.
  • the term “regular disaccharide” may refer to a disaccharide that does not contain an anhydro-subunit.
  • the term “regular subunit” may refer to a subunit that is not an anhydro-subunit.
  • relative abundance may refer to the abundance of a species in terms of how common or rare the species exists.
  • a DP1 fraction comprising 10% anhydro-subunit containing oligosaccharides by relative abundance may refer to a plurality of DP1 oligosaccharides, wherein 10%, by number, of the DP1 oligosaccharides are anhydro-monosaccharides.
  • a distribution of the degree of polymerization of the oligosaccharide preparation may be determined by any suitable analytical method and instrumentation, including but not limited to end group method, osmotic pressure (osmometry), ultracentrifugation, viscosity measurements, light scattering method, size exclusion chromatography (SEC), SEC-MALLS, field flow fractionation (FFF), asymmetric flow field flow fractionation (A4F), high-performance liquid chromatography (HPLC), and mass spectrometry (MS).
  • the distribution of the degree of polymerization may be determined and/or detected by mass spectrometry, such as MALDI-MS, LC-MS, or GC-MS.
  • the distribution of the degree of polymerization may be determined and/or detected by SEC, such as gel permeation chromatography (GPC).
  • the distribution of the degree of polymerization may be determined and/or detected by HPLC, FFF, orA4F.
  • the degree of polymerization of the oligosaccharide preparation may be determined based on its molecular weight and molecular weight distribution (for a more detailed description see WO 2020/097458).
  • each of the n fractions of oligosaccharides of the oligosaccharide preparation as described herein independently comprises an anhydrosubunit level.
  • the DP1 fraction comprises 10% anhydrosubunit containing oligosaccharides by relative abundance
  • the DP2 fraction comprises 15% anhydro-subunit containing oligosaccharides by relative abundance.
  • DP1 , DP2, and DP3 fraction each comprises 5%, 10%, and 2% anhydrosubunit containing oligosaccharides by relative abundance, respectively.
  • two or more fractions of oligosaccharides may comprise similar level of anhydro-subunit containing oligosaccharides.
  • the DP1 and DP3 fraction each comprises about 5 % anhydro-subunit containing oligosaccharides by relative abundance.
  • the level of anhydro-subunits may be determined by any suitable analytical methods, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, HPLC, FFF, A4F, or any combination thereof.
  • the level of anhydro-subunits is determined, at least in part, by mass spectrometry such as MALDI-MS.
  • the level of anhydro-subunits may be determined, at least in part, by NMR.
  • the level of anhydro-subunits may be determined, at least in part, by HPLC.
  • the level of anhydro-subunits may be determined by MALDI-MS, as illustrated in more detail in WO 2020/097458.
  • the oligosaccharide preparation described herein comprise a variety of glycosidic linkages.
  • the type and distribution of the glycosidic linkages may depend on the source and manufacturing method of the oligosaccharide preparation.
  • the type and distribution of various glycosidic linkages may be determined and/or detected by any suitable methods known in the art such as NMR.
  • the glycosidic linkages are determined and/or detected by proton NMR, carbon NMR, 2D NMR such as 2D JRES, HSQC, HMBC, DOSY, COSY, ECOSY, TOCSY, NOESY, or ROESY, or any combination thereof.
  • the glycosidic linkages are determined and/or detected, at least in part, by proton NMR. In some embodiments, the glycosidic linkages are determined and/or detected, at least in part, by carbon NMR. In some embodiments, the glycosidic linkages are determined and/or detected, at least in part, by 2D HSQC NMR.
  • an oligosaccharide preparation may comprise one or more a-(1 ,2) glycosidic linkages, a-(1 ,3) glycosidic linkages, a-(1 ,4) glycosidic linkages, a-(1 ,6) glycosidic linkages,
  • the oligosaccharide preparations have a glycosidic bond type distribution of about from 0 to 60 mol%, 5 to 55 mol%, 5 to 50 mol%, 5 to 45 mol%, 5 to 40 mol%, 5 to 35 mol%, 5 to 30 mol%, 5 to 25 mol%, 10 to 60 mol%, 10 to 55 mol%, 10 to 50 mol%, 10 to 45 mol%, 10 to 40 mol%, 10 to 35 mol%, 15 to 60 mol%, 15 to 55 mol%, 15 to 50 mol%, 15 to 45 mol%, 15 to 40 mol%, 15 to 35 mol%, 20 to 60 mol%, 20 to 55 mol%, 20 to 50 mol%, 20 to 45 mol%, 20 to 40 mol%, 20 to 35 mol%, 25 to 60 mol%, 25 to 55 mol%, 25 to 50 mol%, 25 to 45 mol%, 25 to 40 mol%, or 25 to 35 mol%,
  • the molecular weight and molecular weight distribution of the oligosaccharide preparation may be determined by any suitable analytical means and instrumentation, such as end group method, osmotic pressure (osmometry), ultracentrifugation, viscosity measurements, light scattering method, SEC, SEC-MALLS, FFF, A4F, HPLC, and mass spectrometry.
  • the molecular weight and molecular weight distribution are determined by mass spectrometry, such as MALDI-MS, LC-MS, or GC-MS.
  • the molecular weight and molecular weight distribution are determined by size exclusion chromatography (SEC), such as gel permeation chromatography (GPC).
  • SEC size exclusion chromatography
  • GPC gel permeation chromatography
  • the molecular weight and molecular weight distribution are determined by HPLC.
  • the molecular weight and molecular weight distribution are determined by MALDI-MS.
  • the weight average molecular weight of the oligosaccharide preparation is about from 100 to 10000 g/mol, 200 to 8000 g/mol, 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 900 to 5000 g/mol, 1100 to 5000 g/mol, 1300 to 5000 g/mol, 1500 to 5000 g/mol, 1700 to 5000 g/mol, 300 to 4500 g/mol, 500 to 4500 g/mol, 700 to 4500 g/mol, 900 to 4500 g/mol, 1100 to 4500 g/mol, 1300 to 4500 g/mol, 1500 to 4500 g/mol, 1700 to 4500 g/mol, 1900 to 4500 g/mol, 300 to 4000 g/mol, 500 to 4000 g/mol, 700 to 4000 g/mol, 900 to 4000 g/mol, 1100 to 4000 g/mol,
  • the weight average molecular weight of the oligosaccharide preparation is about from 2000 to 2800 g/mol, 2100 to 2700 g/mol, 2200 to 2600 g/mol, 2300 to 2500 g/mol, or 2320 to 2420 g/mol.
  • the species of oligosaccharides present in an oligosaccharide preparation referred to herein may depend on the type of the one or more feed sugars.
  • the oligosaccharide preparations comprise a gluco-oligosaccharide when the feed sugars comprise glucose.
  • the oligosaccharide preparations comprise a galacto-oligosaccharide when the feed sugars comprise galactose.
  • the oligosaccharide preparations comprise gluco-galacto-oligosaccharides when the feed sugars comprise galactose and glucose.
  • the oligosaccharide preparations comprise one or more species of monosaccharide subunits.
  • the oligosaccharide preparation may comprise oligosaccharides with 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, or more different species of monosaccharides subunits.
  • the polymerization of the feed sugars is achieved by a step-growth polymerization. In some embodiments, the polymerization of the feed sugars is achieved by polycondensation.
  • Feed Sugar The one or more feed sugars used in the methods of manufacturing oligosaccharide preparations described herein may comprise one or more types of sugars. In some embodiments, the one or more feed sugars comprise monosaccharides, disaccharides, trisaccharides, tetrasaccharides, or any mixtures thereof.
  • the one or more feed sugars comprise glucose. In some embodiments, the one or more feed sugars comprise glucose and galactose. In some embodiments, the one or more feed sugars comprise glucose, xylose, and galactose. In some embodiments, the one or more feed sugars comprise glucose and mannose. In some embodiments, the one or more feed sugars comprise glucose and fructose. In some embodiments, the one or more feed sugars comprise glucose, fructose, and galactose. In some embodiments, the one or more feed sugars comprise glucose, galactose, and mannose.
  • the singular forms “a,” “and,” and “the” include plural referents unless the context clearly dictates otherwise.
  • reference to “an agent” includes a plurality of such agents
  • reference to “the oligosaccharide” includes reference to one or more oligosaccharides (or to a plurality of oligosaccharides) and equivalents thereof known to those skilled in the art, and so forth.
  • the invention is further characterized by the following items:
  • Item 1 Method for reducing necrotic enteritis effect in a bird, comprising the step of administering an oligosaccharide preparation to a bird in need of reducing necrotic enteritis effect, wherein the oligosaccharide preparation comprises at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than or equal to 2; and wherein each fraction comprises from at least about 0.5% to about 90%, e.g. from 1 % to 90%, or e.g. from about 0.5% to about 15%, of anhydrosubunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • Item 2 The method of item 1 , wherein the necrotic enteritis effect is at least one selected from the group of reduced body weight gain of the bird in need of reducing necrotic enteritis effect compared to a control bird not in need of reducing necrotic enteritis effect; increased feed conversion ratio of the bird in need of reducing necrotic enteritis effect compared to the control bird; increased mortality of the bird in need of reducing necrotic enteritis effect compared to the control bird; and increased lesion score of the bird in need of reducing necrotic enteritis effect compared to the control bird.
  • Item 3 The method of item 1 or 2, wherein the bird in need of reducing necrotic enteritis effect is challenged by Clostridium perfringens.
  • Item 4 The method of any one of the preceding items, wherein the oligosaccharide preparation is comprised in a nutritional composition administered to the bird.
  • Item 5 The method of any one of the preceding items, wherein the oligosaccharide preparation is comprised in the nutritional composition at an inclusion rate of at least 50 ppm, e.g. at least 50, 70, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900 ppm.
  • Item 6 The method of any one of the preceding items, wherein the oligosaccharide preparation is administered to the bird before, after, and/or simultaneously with the diet of the bird in need of reducing necrotic enteritis effect , preferably simultaneously with the diet.
  • Item 7 The method of any one of the preceding items, wherein the bird is poultry, e.g. chicken, duck, goose, turkey, guinea fowl, pigeon, quail; preferably chicken.
  • poultry e.g. chicken, duck, goose, turkey, guinea fowl, pigeon, quail; preferably chicken.
  • Item 8 The method of any one of the preceding items, wherein the necrotic enteritis effect is reduced on at least one day within 42 days after a first administration of the oligosaccharide preparation, selected from the group of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42 day(s).
  • Item 9 The method of any one of the preceding items, wherein n of the oligosaccharide preparation is at Ieast 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 100.
  • Item 10 The method of any one of the preceding items, wherein at least one fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance; and/or wherein each fraction of the oligosaccharide preparation comprises greater than 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 11 The method of any one of the preceding items, wherein the oligosaccharide preparation has a weight average molecular weight from about 300 to 5000 g/mol, e.g. from about 2000 to 2800 g/mol, 2100 to 2700 g/mol, 2200 to 2600 g/mol, 2300 to 2500 g/mol, or 2320 to
  • the oligosaccharide preparation has a number average molecular weight from about 1000 to 2000 g/mol, 1100 to 1900 g/mol, 1200 to 1800 g/mol, 1300 to 1700 g/mol, 1400 to 1600 g/mol, or 1450 to 1550 g/mol.
  • Item 12 The method of any one of the preceding items, wherein the relative abundance of oligosaccharides in each of the n fractions of the oligosaccharide preparation decreases monotonically with its degree of polymerization.
  • Item 13 The method according to any one of the preceding items, wherein the relative abundance of oligosaccharides in at least 5, 10, 20, or 30 DP fractions of the oligosaccharide preparation decreases monotonically with its degree of polymerization.
  • Item 14 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 15 The method according to any one of the preceding items, wherein each fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 16 The method according to any one of the preceding items, wherein at least one fraction of the oligosaccharide preparation comprises greater than 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 17 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises greater than 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 18 The method according to any one of the preceding items, wherein each fraction of the oligosaccharide preparation comprises greater than 20%, 21%, 22%, 23%, 24%, or 25% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 19 The method according to any one of the preceding items, wherein more than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30% of the anhydro-subunit containing oligosaccharides of the oligosaccharide preparation have only one anhydro-subunit.
  • Item 20 The method according to any one of the preceding items, wherein the oligosaccharide preparation has a DP1 fraction content from 1 to 40 % by relative abundance.
  • Item 21 The method according to any one of the preceding items, wherein the oligosaccharide preparation has a DP2 fraction content from 1 to 35 % by relative abundance.
  • Item 22 The method according to any one of the preceding items, wherein the oligosaccharide preparation has a DP3 fraction content from 1 to 30 % by relative abundance.
  • Item 23 The method according to any one of the preceding items, wherein the oligosaccharide preparation has a DP4 fraction content from 0.1 to 20 % by relative abundance.
  • Item 24 The method according to any one of the preceding items, wherein the oligosaccharide preparation has a DP5 fraction content from 0.1 to 15 % by relative abundance.
  • Item 25 The method according to any one of the preceding items, wherein the ratio of DP2 fraction to DP1 fraction of the oligosaccharide preparation is 0.02-0.40 by relative abundance.
  • Item 26 The method according to any one of the preceding items, wherein the ratio of DP3 fraction to DP2 fraction of the oligosaccharide preparation is 0.01-0.30 by relative abundance.
  • Item 27 The method according to any one of the preceding items, wherein the aggregate content of DP1 and DP2 fractions in the oligosaccharide preparation is less than 50, 30, or 10% by relative abundance.
  • Item 28 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises at least 103, 104, 105, 106 or 109 different oligosaccharide species.
  • Item 29 The method according to any one of the preceding items, wherein two or more independent oligosaccharides of the oligosaccharide preparation comprise different anhydrosubunits.
  • Item 30 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises one or more anhydro-subunits that are products of reversible thermal dehydration of monosaccharides.
  • Item 31 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises one or more anhydro-glucose, anhydro-galactose, anhydro-mannose, anhydro-allose, anhydro-altrose, anhydro-gulose, anhydro-indose, anhydro- talose, anhydro-fructose, anhydro-ribose, anhydro-arabinose, anhydro-rhamnose, anhydro- lyxose, or anhydro-xylose subunits.
  • Item 32 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises one or more anhydro-glucose, anhydro-galactose, anhydro-mannose, or anhydro-fructose subunits.
  • Item 33 The method according to any one of the preceding items, wherein the oligosaccharide preparation comprises one or more 1,6-anhydro-p-D-glucofuranose or 1,6- anhydro-p-D-glucopyranose subunits. In some embodiments, the oligosaccharide preparation comprises both 1,6-anhydro-p-D-glucofuranose and 1 ,6-anhydro-p-D-glucopyranose anhydrosubunits.
  • Item 34 The method according to any one of the preceding items, wherein a ratio of 1 ,6- anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is from about 10:1 to 1 :10, 9:1 to 1 :10, 8:1 to 1:10, 7:1 to 1 :10, 6:1 to 1 :10, 5:1 to 1 :10, 4:1 to 1 :10, 3:1 to 1 :10, 2:1 to 1 :10, 10:1 to 1:9, 10:1 to 1:8, 10:1 to 1:7, 10:1 to 1 :6, 10:1 to 1 :5, 10:1 to 1:4, 10:1 to 1:3, 10:1 to 1 :2, or 1:1 to 3:1 in the oligosaccharide preparation.
  • Item 35 The method according to any one of the preceding items, wherein the ratio of 1 ,6-anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is about 10:1 , 9:1 , 8:1 , 7:1, 6:1 , 5:1, 4:1, 3:1, 2:1 , 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1 :7, 1:8, 1:8, 1:9, or 1:10 within the oligosaccharide preparation.
  • Item 36 The method according to any one of the preceding items, wherein the ratio of 1 ,6-anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is about 2:1 in the oligosaccharide preparation.
  • Item 37 The method according to any one of the preceding items, wherein the ratio of
  • 1 ,6-anhydro-p-D-glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about from 10:1 to 1 : 10, 9: 1 to 1 :10, 8:1 to 1 :10, 7:1 to 1 :10, 6:1 to 1 :10, 5:1 to 1 :10, 4:1 to 1 :10, 3:1 to 1 :10, 2:1 to 1 :10, 10:1 to 1 :9, 10:1 to 1 :8, 10:1 to 1 :7, 10:1 to 1 :6, 10:1 to 1 :5, 10:1 to 1 :4, 10:1 to 1 :3, 10:1 to 1 :2, or 1 :1 to 3:1 in each fraction of the oligosaccharide preparation.
  • Item 38 The method according to any one of the preceding items, wherein the ratio of
  • 1 ,6-anhydro-p-D-glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :8, 1 :9, or 1 :10 in each fraction of the oligosaccharide preparation.
  • Item 39 The method according to any one of the preceding items, wherein the ratio of
  • 1 ,6-anhydro-p-D-glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about 2:1 in each fraction of the oligosaccharide preparation.
  • Item 40 The method according to any one of the preceding items, wherein at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of anhydro-subunits in the oligosaccharide preparation are selected from a group consisting of 1 ,6-anhydro-p-D- glucofuranose and 1 ,6-anhydro-p-D-glucopyranose.
  • Item 41 The method according to any one of the preceding items, wherein the weight average molecular weight of the oligosaccharide preparation is about from 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1300 g/mol, 400 to 1200 g/mol, 400 to 1100 g/mol, 500 to 1300 g/mol, 500 to 1200 g/mol, 500 to 1100 g/mol, 600 to 1300 g/mol, 600 to 1200 g/mol, or 600 to 1100 g/mol.
  • Item 42 The method according to any one of the preceding items, wherein the number average molecular weight of the oligosaccharide preparation is about from 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1000 g/mol, 400 to 900 g/mol, 400 to 800 g/mol, 500 to 900 g/mol, or 500 to 800 g/mol.
  • Item 43 The method according to any one of the preceding items, wherein the distribution of the degree of polymerization is determined and/or detected by MALDI-MS, GC-MS, LC-MS, SEC, HPLC and/or combination(s) thereof (e.g. MALDI-MS and SEC).
  • Item 44 The method according to any one of the preceding items, wherein the degree of polymerization of the oligosaccharide preparation may be determined based on its molecular weight and molecular weight distribution.
  • Item 45 The method according to any one of the preceding items, wherein the oligosaccharide preparation is comprised in the nutritional composition at a concentration of at least 50 g per ton of feed (e.g.
  • the oligosaccharide preparation comprised in the nutritional composition at least 70 g, 100 g, 200 g, 300 g, 400 g, 500 g, 600 g, 700 g, 800 g, 900 g per ton of feed); and/or wherein the oligosaccharide preparation comprised in the nutritional composition at an inclusion rate of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm); and/or wherein the oligosaccharide preparation comprised in the nutritional composition at a concentration of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm).
  • the oligosaccharide preparation comprised in the nutritional composition at a concentration of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm).
  • Item 46 The method according to any one of the preceding items, wherein the oligosaccharide preparation is administered for at least one day, preferably for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32,
  • the nutritional composition is administered continuously, i.e. uninterruptedly.
  • Item 47 Use of an oligosaccharide preparation for reducing necrotic enteritis effect in a bird in need thereof, wherein the oligosaccharide preparation comprises at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than or equal to 2; and wherein each fraction comprises from at least about 0.5% to about 90%, e.g. from 1% to 90%, or e.g. from about 0.5% to about 15%, of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • Item 48 The use of item 47, wherein n of the oligosaccharide preparation is at least 3,
  • Item 49 The use of item 47 or 48, wherein at least one fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance; and/or wherein each fraction of the oligosaccharide preparation comprises greater than 0.2%, 0.5%, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 30%, 40%
  • Item 50 The use of any one of items 47-49, wherein the oligosaccharide preparation has a weight average molecular weight from about 300 to 5000 g/mol, e.g. from about 2000 to 2800 g/mol, 2100 to 2700 g/mol, 2200 to 2600 g/mol, 2300 to 2500 g/mol, or 2320 to 2420 g/mol; 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1300 g/mol, 400 to 1200 g/mol, 400 to 1100 g/mol, 500 to 1300 g/mol, 500 to 1200 g/mol, 500 to 1100 g/mol, 600 to 1300 g/mol, 600 to 1200 g/mol, or 600 to 1100 g/mol; and/or wherein the oligo
  • Item 51 The use of any one of items 47-50, wherein the relative abundance of oligosaccharides in each of the n fractions of the oligosaccharide preparation decreases monotonically with its degree of polymerization.
  • Item 52 The use of any one of items 47-51 , wherein the relative abundance of oligosaccharides in at least 5, 10, 20, or 30 DP fractions of the oligosaccharide preparation decreases monotonically with its degree of polymerization.
  • Item 53 The use of any one of items 47-52, wherein the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 54 The use of any one of items 47-53, wherein each fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 55 The use of any one of items 47-54, wherein at least one fraction of the oligosaccharide preparation comprises greater than 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 56 The use of any one of items 47-55, wherein the oligosaccharide preparation comprises greater than 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, or 25%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 57 The use of any one of items 47-56, wherein each fraction of the oligosaccharide preparation comprises greater than 20%, 21 %, 22%, 23%, 24%, or 25% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 58 The use of any one of items 47-57, wherein more than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30% of the anhydro-subunit containing oligosaccharides of the oligosaccharide preparation have only one anhydro-subunit.
  • Item 59 The use of any one of items 47-58, wherein the oligosaccharide preparation has a DP1 fraction content from 1 to 40 % by relative abundance.
  • Item 60 The use of any one of items 47-59, wherein the oligosaccharide preparation has a DP2 fraction content from 1 to 35 % by relative abundance.
  • Item 61 The use of any one of items 47-60, wherein the oligosaccharide preparation has a DP3 fraction content from 1 to 30 % by relative abundance.
  • Item 62 The use of any one of items 47-61 , wherein the oligosaccharide preparation has a DP4 fraction content from 0.1 to 20 % by relative abundance.
  • Item 63 The use of any one of items 47-62, wherein the oligosaccharide preparation has a DP5 fraction content from 0.1 to 15 % by relative abundance.
  • Item 64 The use of any one of items 47-63, wherein the ratio of DP2 fraction to DP1 fraction of the oligosaccharide preparation is 0.02-0.40 by relative abundance.
  • Item 65 The use of any one of items 47-64, wherein the ratio of DP3 fraction to DP2 fraction of the oligosaccharide preparation is 0.01-0.30 by relative abundance.
  • Item 66 The use of any one of items 47-65, wherein the aggregate content of DP1 and DP2 fractions in the oligosaccharide preparation is less than 50, 30, or 10% by relative abundance.
  • Item 67 The use of any one of items 47-66, wherein the oligosaccharide preparation comprises at least 103, 104, 105, 106 or 109 different oligosaccharide species.
  • Item 68 The use of any one of items 47-67, wherein two or more independent oligosaccharides of the oligosaccharide preparation comprise different anhydro-subunits.
  • Item 69 The use of any one of items 47-68, wherein the oligosaccharide preparation comprises one or more anhydro-subunits that are products of reversible thermal dehydration of monosaccharides.
  • Item 70 The use of any one of items 47-69, wherein the oligosaccharide preparation comprises one or more anhydro-glucose, anhydro-galactose, anhydro-mannose, anhydro-allose, anhydro-altrose, anhydro-gulose, anhydro-indose, anhydro-talose, anhydro-fructose, anhydroribose, anhydro-arabinose, anhydro-rhamnose, anhydro-lyxose, or anhydro-xylose subunits.
  • the oligosaccharide preparation comprises one or more anhydro-glucose, anhydro-galactose, anhydro-mannose, anhydro-allose, anhydro-altrose, anhydro-gulose, anhydro-indose, anhydro-talose, anhydro-fructose, anhydroribose, anhydro-arabinose, anhydro-
  • Item 71 The use of any one of items 47-70, wherein the oligosaccharide preparation comprises one or more anhydro-glucose, anhydro-galactose, anhydro-mannose, or anhydrofructose subunits.
  • Item 72 The use of any one of items 47-71, wherein the oligosaccharide preparation comprises one or more 1,6-anhydro-p-D-glucofuranose or 1,6-anhydro-p-D-glucopyranose subunits. In some embodiments, the oligosaccharide preparation comprises both 1,6-anhydro-p- D-glucofuranose and 1,6-anhydro-p-D-glucopyranose anhydro-subunits.
  • Item 73 The use of any one of items 47-72, wherein a ratio of 1,6-anhydro-p-D- glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is from about 10:1 to 1:10, 9:1 to 1:10, 8:1 to 1:10, 7:1 to 1:10, 6:1 to 1:10, 5:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 10:1 to 1:9, 10:1 to 1:8, 10:1 to 1:7, 10:1 to 1:6, 10:1 to 1:5, 10:1 to 1:4, 10:1 to 1:3, 10:1 to 1:2, or 1:1 to 3:1 in the oligosaccharide preparation.
  • Item 74 The use of any one of items 47-73, wherein the ratio of 1,6-anhydro-p-D- glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:8, 1:9, or 1:10 within the oligosaccharide preparation.
  • Item 75 The use of any one of items 47-74, wherein the ratio of 1,6-anhydro-p-D- glucofuranose to 1,6-anhydro-p-D-glucopyranose is about 2:1 in the oligosaccharide preparation.
  • Item 76 The use of any one of items 47-75, wherein the ratio of 1,6-anhydro-p-D- glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about from 10:1 to 1:10, 9:1 to 1:10, 8:1 to 1:10, 7:1 to 1:10, 6:1 to 1:10, 5:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 10:1 to 1:9, 10:1 to 1:8, 10:1 to 1:7, 10:1 to 1:6, 10:1 to 1:5, 10:1 to 1:4, 10:1 to 1:3, 10:1 to 1:2, or 1:1 to 3:1 in each fraction of the oligosaccharide preparation.
  • Item 77 The use of any one of items 47-76, wherein the ratio of 1,6-anhydro-p-D- glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:8, 1:9, or 1:10 in each fraction of the oligosaccharide preparation.
  • Item 78 The use of any one of items 47-77, wherein the ratio of 1 ,6-anhydro-p-D- glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about 2:1 in each fraction of the oligosaccharide preparation.
  • Item 79 The use of any one of items 47-78, wherein at least 1 %, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of anhydro-subunits in the oligosaccharide preparation are selected from a group consisting of 1 ,6-anhydro-p-D-glucofuranose and 1 ,6-anhydro-p-D- glucopyranose.
  • Item 80 The use of any one of items 47-79, wherein the weight average molecular weight of the oligosaccharide preparation is about from 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1300 g/mol, 400 to 1200 g/mol, 400 to 1100 g/mol, 500 to 1300 g/mol, 500 to 1200 g/mol, 500 to 1100 g/mol, 600 to 1300 g/mol, 600 to 1200 g/mol, or 600 to 1100 g/mol.
  • Item 81 The use of any one of items 47-80, wherein the number average molecular weight of the oligosaccharide preparation is about from 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1000 g/mol, 400 to 900 g/mol, 400 to 800 g/mol, 500 to 900 g/mol, or 500 to 800 g/mol.
  • Item 82 The use of any one of items 47-81 , wherein the distribution of the degree of polymerization is determined and/or detected by MALDI-MS, GC-MS, LC-MS, SEC, HPLC and/or combination(s) thereof (e.g. MALDI-MS and SEC).
  • Item 83 The use of any one of items 47-84, wherein the degree of polymerization of the oligosaccharide preparation may be determined based on its molecular weight and molecular weight distribution.
  • Item 84 The use of any one of items 47-83, wherein the oligosaccharide preparation is comprised in the nutritional composition at a concentration of at least 50 g per ton of feed (e.g. at least 70 g, 100 g, 200 g, 300 g, 400 g, 500 g, 600 g, 700 g, 800 g, 900 g per ton of feed); and/or wherein the oligosaccharide preparation comprised in the nutritional composition at an inclusion rate of at least 50 ppm (e.g.
  • the oligosaccharide preparation comprised in the nutritional composition at a concentration of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm).
  • Item 85 The use of any one of items 47-84, wherein the oligosaccharide preparation is administered for at least one day, preferably for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, 100, 101
  • the nutritional composition is administered continuously, i.e. uninterruptedly.
  • Item 86 Oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof, wherein the oligosaccharide preparation comprises at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than or equal to 2; and wherein each fraction comprises from at least about 0.5% to about 90%, e.g. from 1% to 90%, or e.g. from about 0.5% to about 15%, of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • Item 87 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of item 86, wherein n of the oligosaccharide preparation is at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18,
  • Item 88 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of item 86 or item 87, wherein at least one fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance; and/or wherein each fraction of the oligosaccharide preparation comprises greater than 0.2%, 0.5%, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 30%, 40%, 50%,
  • Item 89 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86- 88, wherein the oligosaccharide preparation has a weight average molecular weight from about 300 to 5000 g/mol, e.g.
  • oligosaccharide preparation has a number average molecular weight from about 1000 to 2000 g/mol, 1100 to 1900 g/mol, 1200 to 1800 g/mol, 1300 to 1700 g/mol, 1400
  • Item 90 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items SOSO, wherein the relative abundance of oligosaccharides in each of the n fractions of the oligosaccharide preparation decreases monotonically with its degree of polymerization.
  • Item 91 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 92 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 93 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • each fraction of the oligosaccharide preparation comprises less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11 %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 94 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • At least one fraction of the oligosaccharide preparation comprises greater than 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 95 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86- 94, wherein the oligosaccharide preparation comprises greater than 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, or 25%, 30%, 40%, 50%, 60%, 70%, or 80% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 96 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • each fraction of the oligosaccharide preparation comprises greater than 20%, 21%, 22%, 23%, 24%, or 25% anhydro-subunit containing oligosaccharides by relative abundance.
  • Item 97 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 98 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • oligosaccharide preparation has a DP1 fraction content from 1 to 40 % by relative abundance.
  • Item 99 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • oligosaccharide preparation has a DP2 fraction content from 1 to 35 % by relative abundance.
  • Item 100 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the oligosaccharide preparation has a DP3 fraction content from 1 to 30 % by relative abundance.
  • Item 101 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the oligosaccharide preparation has a DP4 fraction content from 0.1 to 20 % by relative abundance.
  • Item 102 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 103 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 104 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 105 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the aggregate content of DP1 and DP2 fractions in the oligosaccharide preparation is less than 50, 30, or 10% by relative abundance.
  • Item 106 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • oligosaccharide preparation comprises at least 103, 104, 105, 106 or 109 different oligosaccharide species.
  • Item 107 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 108 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • oligosaccharide preparation comprises one or more anhydro-subunits that are products of reversible thermal dehydration of monosaccharides.
  • Item 109 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the oligosaccharide preparation comprises one or more anhydro-glucose, anhydrogalactose, anhydro-mannose, anhydro-allose, anhydro-altrose, anhydro-gulose, anhydro-indose, anhydro-talose, anhydro-fructose, anhydro-ribose, anhydro-arabinose, anhydro-rhamnose, anhydro-lyxose, or anhydro-xylose subunits.
  • Item 110 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 111 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86- 110, wherein the oligosaccharide preparation comprises one or more 1,6-anhydro-p-D- glucofuranose or 1,6-anhydro-p-D-glucopyranose subunits.
  • the oligosaccharide preparation comprises both 1 ,6-anhydro-p-D-glucofuranose and 1 ,6-anhydro-p- D-glucopyranose anhydro-subunits.
  • Item 112 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86- 112, wherein a ratio of 1,6-anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is from about 10:1 to 1:10, 9:1 to 1:10, 8:1 to 1:10, 7:1 to 1:10, 6:1 to 1:10, 5:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 10:1 to 1:9, 10:1 to 1:8, 10:1 to 1:7, 10:1 to 1:6, 10:1 to 1:5, 10:1 to 1:4, 10:1 to 1:3, 10:1 to 1:2, or 1:1 to 3:1 in the oligosaccharide preparation.
  • Item 113 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • 1,6-anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:8, 1:9, or 1:10 within the oligosaccharide preparation.
  • Item 114 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • Item 115 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • ratio of 1,6-anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is about from 10:1 to 1:10, 9:1 to 1:10, 8:1 to 1:10, 7:1 to 1:10, 6:1 to 1:10, 5:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 10:1 to 1:9, 10:1 to 1:8, 10:1 to 1:7, 10:1 to 1:6, 10:1 to 1:5, 10:1 to 1:4, 10:1 to 1:3, 10:1 to 1:2, or 1:1 to 3:1 in each fraction of the oligosaccharide preparation.
  • Item 116 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items Sell 5, wherein the ratio of 1,6-anhydro-p-D-glucofuranose to 1,6-anhydro-p-D-glucopyranose is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:8, 1:9, or 1:10 in each fraction of the oligosaccharide preparation.
  • Item 117 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86- 116, wherein the ratio of 1 ,6-anhydro-p-D-glucofuranose to 1 ,6-anhydro-p-D-glucopyranose is about 2:1 in each fraction of the oligosaccharide preparation.
  • Item 118 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items Sel l 7, wherein at least 1 %, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of anhydrosubunits in the oligosaccharide preparation are selected from a group consisting of 1 ,6-anhydro- P-D-glucofuranose and 1 ,6-anhydro-p-D-glucopyranose.
  • Item 119 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items Sel l 8, wherein the weight average molecular weight of the oligosaccharide preparation is about from 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1300 g/mol, 400 to 1200 g/mol, 400 to 1100 g/mol, 500 to 1300 g/mol, 500 to 1200 g/mol, 500 to 1100 g/mol, 600 to 1300 g/mol, 600 to 1200 g/mol, or 600 to 1100 g/mol.
  • Item 120 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items Sel l 9, wherein the number average molecular weight of the oligosaccharide preparation is about from 300 to 5000 g/mol, 500 to 5000 g/mol, 700 to 5000 g/mol, 500 to 2000 g/mol, 700 to 2000 g/mol, 700 to 1500 g/mol, 300 to 1500 g/mol, 300 to 2000 g/mol, 400 to 1000 g/mol, 400 to 900 g/mol, 400 to 800 g/mol, 500 to 900 g/mol, or 500 to 800 g/mol.
  • Item 121 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the distribution of the degree of polymerization is determined and/or detected by MALDI-MS, GC-MS, LC-MS, SEC, HPLC and/or combination(s) thereof (e.g. MALDI-MS and SEC).
  • Item 122 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the degree of polymerization of the oligosaccharide preparation may be determined based on its molecular weight and molecular weight distribution.
  • Item 123 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86-
  • the oligosaccharide preparation is comprised in the nutritional composition at a concentration of at least 50 g per ton of feed (e.g. at least 70 g, 100 g, 200 g, 300 g, 400 g, 500 g, 600 g, 700 g, 800 g, 900 g per ton of feed); and/or wherein the oligosaccharide preparation comprised in the nutritional composition at an inclusion rate of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm); and/or wherein the oligosaccharide preparation comprised in the nutritional composition at a concentration of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm).
  • the oligosaccharide preparation comprised in the nutritional composition at a concentration of at least 50 ppm (e.g. at least 50, 70, 100, 150, 200, 300, 400, 500 ppm).
  • Item 124 The oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis of a bird suffering from necrotic enteritis and/or in risk thereof of any one of items 86- 123, wherein the oligosaccharide preparation is administered for at least one day, preferably for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85,
  • the nutritional composition is administered continuously, i.e. uninterruptedly.
  • the oligosaccharide preparation referred to herein may be characterized by any one, two or more or even all of the individual oligosaccharide preparation features as described in the items above.
  • the oligosaccharide preparation may be characterized by any combination of the individual features of the oligosaccharide preparation described in the items above.
  • the oligosaccharide preparation may be characterized by a combination of the combined oligosaccharide preparation features as described in items 9, 11 , 20 and 39.
  • Example 1 Effect of oligosaccharide preparation on birds subjected to necrotic enteritis challenge
  • a feeding trial was performed to study the effects of oligosaccharide preparations on zootechnical and biological parameters of broiler chickens undergoing a necrotic enteritis challenge model created by Eimeria maxima and Clostridium perfringens inoculation.
  • Oligosaccharide preparations were prepared as disclosed in WO 2020/097458 and WO 2016/007778, in particular in any one of Examples 1-7, 16-18 of WO 2020/097458 A1 , in the methods described in paragraph [317], and/or in any one of Examples 73-77, 80-89, 97-99, 101- 110 of WO 2016/007778 A1.
  • the oligosaccharide preparations comprise at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than 3; wherein each of a DP1 and DP2 fraction independently comprises from about 0.5% to about 15% of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry.
  • the prepared oligosaccharide preparations can be characterized by the features described herein.
  • Trial duration was 42 days. All birds received vaccination against coccidiosis (COCCIVAC®-B52 by Merck Animal Health USA, a live oocysts vaccine isolated from chickens, prepared from anticoccidial-sensitive strains of E. acervulina, E. maxima, E. maxima MFP, E. mivati, and E. tenella according to the product bulletin).
  • COCCIVAC®-B52 by Merck Animal Health USA, a live oocysts vaccine isolated from chickens, prepared from anticoccidial-sensitive strains of E. acervulina, E. maxima, E. maxima MFP, E. mivati, and E. tenella according to the product bulletin).
  • a negative control group was not subjected to necrotic enteritis challenge, and was not administered the oligosaccharide preparation.
  • a challenge control group was subjected to necrotic enteritis challenge, but not administered the oligosaccharide preparation.
  • a first test group (OP500) was subjected to necrotic enteritis challenge, and was administered feed comprising 500 ppm of the oligosaccharide preparation.
  • a second test group (OP700) was subjected to necrotic enteritis challenge, and was administered feed comprising 700 ppm of the oligosaccharide preparation.
  • a third test group was subjected to necrotic enteritis challenge, and was administered feed comprising 900 ppm of the oligosaccharide preparation.
  • the temperature of the building was monitored. Environmental conditions during the trial (temperature) were appropriate (optimum) to the age of the animals. Illumination was provided by fluorescent bulbs placed above the pens. The lighting scheme was 22 light and 2 dark hours per day. Standard floor pen management practices were used throughout the experiment. Animals and housing facilities were inspected twice daily, observing, and recording the general health status, constant feed and water supply as well as temperature, removing all dead birds, and recognizing unexpected events.
  • Pens were checked daily for mortality. A bird was culled only to relieve suffering. When a bird was culled or found dead, the pen, date and removal weight (kg) were recorded. A gross necropsy was performed on all dead or culled birds to determine the probable cause of death.
  • CP6 Clostridium perfringens
  • Fresh inoculum was used each day with a titration level of approximately 1 .0 x 10 8 ’ 9 /bird. Inoculum was administered by mixing into the feed at the base of the tube feeders. Number of days that the CP is given was depended on how much mortality is observed daily. Three days of dosing was used.
  • Coccidia oocysts per gram litter On Day 0 a baseline litter sample was collected for baseline OPG. On day 14, 21 , 28, and 35 fresh fecal samples were collected from each pen. These representative samples were tested to determine the degree of oocysts shedding/cycling. Oocysts per gram was determined for each sample.
  • Necropsy sample collection On Day 21 , 2 birds/pen were randomly selected, sacrificed, individually weighted, and exampled for presence of necrotic enteritis (NE) lesions. From each bird, a section of the ileum was collected into formalin. Formalin was replaced with ethanol 24 hours later and these fixed samples were analyzed for histology based on need determined after analysis of performance data. Similarly, ceca samples were collected and stored in -80°C and analysis determined after reviewing performance data.
  • NE necrotic enteritis
  • Pen weights and feed disappearance Pen weights and feed disappearance were recorded on day 14, 21 , 35, and 42. Feed conversion ratio was calculated.
  • the lesion score characteristic of NE was higher in the CC group than in any of the other groups.
  • groups to which the oligosaccharide preparation was administered had a reduced lesion score compared to the CC group.
  • the necrotic enteritis-challenge promoted a higher frequency of birds with lesion scores 1 and 2 and a drastic reduction in lesion scores 0 in the CC group compared to the NC group.
  • groups receiving the oligosaccharide preparation (OP500, OP700, OP900) reduced the number of birds with lesions 1 and 2 and increased the frequency of birds with lesions 0.
  • administration of the oligosaccharide preparation was found to lead to a reduction in severe lesions despite NE- challenge. Results are summarized in Table 2 below.
  • BWG Body weight gain
  • Fl feed intake
  • FOR feed conversion ratio
  • NE-related mortality NE-mortality
  • FPD foot pad lesions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant de réduire l'effet de l'entérite nécrotique chez un oiseau comprenant l'administration d'une préparation d'oligosaccharide, ainsi qu'une préparation d'oligosaccharide destinée à être utilisée pour traiter ou apporter des améliorations à l'entérite nécrotique chez un oiseau et/ou réduire le risque d'apparition d'une entérite nécrotique chez l'oiseau.
PCT/EP2023/070807 2022-07-29 2023-07-27 Réduction de l'effet de l'entérite nécrotique chez un oiseau à l'aide d'une préparation d'oligosaccharide Ceased WO2024023198A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP23751275.1A EP4561588A1 (fr) 2022-07-29 2023-07-27 Réduction de l'effet de l'entérite nécrotique chez un oiseau à l'aide d'une préparation d'oligosaccharide
CN202380055941.2A CN119604295A (zh) 2022-07-29 2023-07-27 使用寡糖制备物降低禽类坏死性肠炎影响

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263393325P 2022-07-29 2022-07-29
US63/393,325 2022-07-29

Publications (1)

Publication Number Publication Date
WO2024023198A1 true WO2024023198A1 (fr) 2024-02-01

Family

ID=87557563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/070807 Ceased WO2024023198A1 (fr) 2022-07-29 2023-07-27 Réduction de l'effet de l'entérite nécrotique chez un oiseau à l'aide d'une préparation d'oligosaccharide

Country Status (3)

Country Link
EP (1) EP4561588A1 (fr)
CN (1) CN119604295A (fr)
WO (1) WO2024023198A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410206B2 (en) 2018-08-21 2025-09-09 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods of use thereof for reducing ammonia levels

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007778A1 (fr) 2014-07-09 2016-01-14 Midori Usa, Inc. Compositions d'oligosaccharides et leurs procédés de production
WO2020097446A1 (fr) * 2018-11-08 2020-05-14 Dsm Ip Assets, B.V. Procédés de soutien de l'homéostasie gastro-intestinale
WO2020097458A1 (fr) 2018-11-08 2020-05-14 Midori Usa, Inc. Préparations et compositions d'oligosaccharides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007778A1 (fr) 2014-07-09 2016-01-14 Midori Usa, Inc. Compositions d'oligosaccharides et leurs procédés de production
WO2020097446A1 (fr) * 2018-11-08 2020-05-14 Dsm Ip Assets, B.V. Procédés de soutien de l'homéostasie gastro-intestinale
WO2020097458A1 (fr) 2018-11-08 2020-05-14 Midori Usa, Inc. Préparations et compositions d'oligosaccharides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABD EL-HACK MOHAMED E. ET AL: "Necrotic enteritis in broiler chickens: disease characteristics and prevention using organic antibiotic alternatives - a comprehensive review", POULTRY SCIENCE, vol. 101, no. 2, 1 February 2022 (2022-02-01), Oxford, pages 101590, XP093093577, ISSN: 0032-5791, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715378/pdf/main.pdf> DOI: 10.1016/j.psj.2021.101590 *
COLLIER ET AL: "Coccidia-induced mucogenesis promotes the onset of necrotic enteritis by supporting Clostridium perfringens growth", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 122, no. 1-2, 19 December 2007 (2007-12-19), pages 104 - 115, XP022494655, ISSN: 0165-2427, DOI: 10.1016/J.VETIMM.2007.10.014 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410206B2 (en) 2018-08-21 2025-09-09 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods of use thereof for reducing ammonia levels

Also Published As

Publication number Publication date
EP4561588A1 (fr) 2025-06-04
CN119604295A (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
JP7699647B2 (ja) 胃腸の恒常性を支持する方法
US20250212913A1 (en) Methods of modulating gastrointestinal metabolites
US12383570B2 (en) Methods of selectively modulating gastrointestinal microbial growth
JP2022506276A (ja) オリゴ糖調製物及び組成物
US20230200412A1 (en) Methods of modulating gastrointestinal microbial metabolic pathways and metabolites
WO2024023198A1 (fr) Réduction de l&#39;effet de l&#39;entérite nécrotique chez un oiseau à l&#39;aide d&#39;une préparation d&#39;oligosaccharide
Bogusławska-Tryk et al. Small intestine morphology and ileal biogenic amines content in broiler chickens fed diets supplemented with lignocellulose
JP5002097B2 (ja) コクシジウムによって引き起こされるヒトまたは動物の病気に対する予防治療剤及びコクシジウムの軽感染に対するヒトまたは動物の免疫のためのアジュバント剤
US20240122953A1 (en) Methods for reducing pathogenic e coli by selective feed additive intervention
US20250041320A1 (en) Use of oligosaccharide preparation to increase performance of animal vaccinated against coccidiosis
Juśiewicz et al. Effect of low-digestible carbohydrates on caecal ammonia concentration in rats and turkeys.
CN118804687A (zh) 使用寡糖制备物改善蛋禽的性能
WO2024208938A1 (fr) Préparation d&#39;oligosaccharides agissant contre les effets d&#39;une maladie respiratoire
EA048816B1 (ru) Способы модуляции желудочно-кишечных метаболитов
EA048774B1 (ru) Способы модуляции желудочно-кишечных метаболитов
El-Saadony et al. ACCEPTED AUTHOR VERSION OF THE MANUSCRIPT
EA044359B1 (ru) Способы и применение синтетического олигосахаридного препарата для повышения эффективности питания животного
EA048821B1 (ru) Способы модуляции желудочно-кишечных метаболитов
EA048800B1 (ru) Способы модуляции желудочно-кишечных метаболитов
EA048829B1 (ru) Способы модуляции желудочно-кишечных метаболитов
EA044964B1 (ru) Способы и применение питательной композиции, содержащей синтетический олигосахаридный препарат
EA045265B1 (ru) Способы модуляции желудочно-кишечных метаболитов

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23751275

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380055941.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023751275

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023751275

Country of ref document: EP

Effective date: 20250228

WWP Wipo information: published in national office

Ref document number: 202380055941.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023751275

Country of ref document: EP